Table 3 Antifungal susceptibility testing results (ATB Fungus 3) of 105 Candida isolates in Shanghai according to new species-specific clinical breakpoints (CBPs) or epidemiologic cutoff values (ECVs) defined by the CLSI[27]
| Â | C. albicans(n=43) | C. parapsilosis(n=24) | C. tropicalis(n=18) | C. glabrata(n=8) | C. guilliermondii(n=7) | C. krusei(n=5) |
|---|---|---|---|---|---|---|
Fluconazole | Â | Â | Â | Â | Â | Â |
Susceptible | 40 (93.0) | 23 (95.8) | 12 (66.7) | 0 (0) | 6 (85.7) | 0 (0) |
SDD | 0 (0) | 0 (0) | 1 (5.5) | 8 (100) | 0 (0) | 0 (0) |
Resistance | 3 (7.0) | 1 (4.2) | 5 (27.8) | 0 (0) | 1 (14.3) | 5 (100) |
Itraconazole | Â | Â | Â | Â | Â | Â |
Susceptible | 34 (79.1) | 23 (95.8) | 11 (61.1) | 4 (50.0) | 5 (71.4) | 1 (20.0) |
SDD | 5 (11.6) | - | - | - | - | - |
Resistance | 4 (9.3) | 1 (4.2) | 7 (38.9) | 4 (50.0) | 2 (28.6) | 4 (80.0) |
Voriconazole | Â | Â | Â | Â | Â | Â |
Susceptible | 41 (95.3) | 23 (95.8) | 13 (72.2) | 8 (100) | 5 (71.4) | 4 (80.0) |
SDD | 0 (0) | 0 (0) | 1 (5.6) | 0 (0) | 0 (0) | 0 (0) |
Resistance | 2 (4.7) | 1 (4.2) | 4 (22.2) | 0 (0) | 2 (28.6) | 1 (20.0) |
Amphotericin B | Â | Â | Â | Â | Â | Â |
Susceptible | 43 (100) | 24 (100) | 18 (100) | 8 (100) | 6 (85.7) | 5 (100) |
Resistance | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (14.3) | 0 (0) |
Flucytosine | Â | Â | Â | Â | Â | Â |
Susceptible | 42 (97.7) | 24 (100) | 18 (100) | 8 (100) | 5 (71.4) | 1 (20.0) |
Resistance | 1 (2.3) | 0 (0) | 0 (0) | 0 (0) | 2 (28.6) | 4 (80.0) |